Nurix Therapeutics (NRIX) Projected to Post Quarterly Earnings on Thursday

Nurix Therapeutics (NASDAQ:NRIX) is anticipated to post its Q2 2026 results before the market opens on Thursday, July 9th. Analysts expect the company to post earnings of ($0.73) per share and revenue of $15.2890 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, July 8, 2026 at 9:30 AM ET.

Nurix Therapeutics (NASDAQ:NRIX) last posted its earnings results on Wednesday, April 8th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.03). The business had revenue of $6.25 million for the quarter, compared to analysts’ expectations of $14.25 million. Nurix Therapeutics had a negative return on equity of 64.21% and a negative net margin of 411.37%. On average, analysts expect Nurix Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Nurix Therapeutics Stock Down 1.4%

Shares of NASDAQ NRIX opened at $23.91 on Thursday. The stock’s 50-day simple moving average is $17.40 and its two-hundred day simple moving average is $17.09. Nurix Therapeutics has a twelve month low of $8.19 and a twelve month high of $24.88. The firm has a market capitalization of $2.47 billion, a P/E ratio of -7.57 and a beta of 1.80.

Insiders Place Their Bets

In other Nurix Therapeutics news, insider Gwenn Hansen sold 5,394 shares of the company’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $20.00, for a total transaction of $107,880.00. Following the completion of the sale, the insider directly owned 115,005 shares in the company, valued at $2,300,100. This represents a 4.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Houte Hans Van sold 14,055 shares of Nurix Therapeutics stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $16.60, for a total value of $233,313.00. Following the completion of the transaction, the chief financial officer owned 37,592 shares in the company, valued at approximately $624,027.20. This represents a 27.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 25,051 shares of company stock worth $434,466. 6.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Nurix Therapeutics

Several institutional investors have recently bought and sold shares of NRIX. Intesa Sanpaolo Wealth Management purchased a new position in Nurix Therapeutics in the 4th quarter worth approximately $31,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Nurix Therapeutics during the fourth quarter valued at approximately $33,000. Wexford Capital LP purchased a new stake in shares of Nurix Therapeutics during the third quarter valued at approximately $41,000. Tower Research Capital LLC TRC grew its holdings in shares of Nurix Therapeutics by 118.3% in the second quarter. Tower Research Capital LLC TRC now owns 6,413 shares of the company’s stock worth $73,000 after purchasing an additional 3,475 shares during the last quarter. Finally, Sherbrooke Park Advisers LLC purchased a new position in shares of Nurix Therapeutics in the third quarter worth $100,000.

Analysts Set New Price Targets

NRIX has been the topic of several research analyst reports. Jefferies Financial Group upped their price objective on shares of Nurix Therapeutics from $41.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, June 8th. Truist Financial raised their price objective on shares of Nurix Therapeutics from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Monday, June 8th. BTIG Research lifted their price objective on shares of Nurix Therapeutics from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, June 9th. Needham & Company LLC reiterated a “buy” rating and issued a $34.00 target price on shares of Nurix Therapeutics in a research report on Monday, June 15th. Finally, HC Wainwright restated a “buy” rating and set a $32.00 price target on shares of Nurix Therapeutics in a research report on Wednesday, June 10th. Fourteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $32.20.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.